Drug Markets/Bimekizumab

Bimekizumab

3 NDCs across 1 manufacturer|0 Generic,3 Brand

Bimekizumab is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.

▸ More about this market

Bimekizumab is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $8016.04 to $8112.59 per ML — a 1% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

3

0G / 3B

Manufacturers

1

competing in market

Price Spread

$8016.04 – $8112.59

per ML

7d Activity

3 flat

avg +0.0% WoW · of 3 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Explore this market from other angles

Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.

Manufacturer Breakdown

1 manufacturer producing BIMEKIZUMAB

Drug Portfolio

3 NDCs total, 3 shown

Drug ↕Price 7d Change ↕
BIMZELX 160 MG/ML AUTOINJECTOR
$8112.5853
per ML
—
BIMZELX 160 MG/ML AUTOINJECTOR
$8035.0733
per ML
—
BIMZELX 320 MG/2 ML AUTOINJECT
$8016.0364
per ML
—

Frequently Asked Questions

What is Bimekizumab used to treat?

Bimekizumab is used to treat psoriasis, per the National Library of Medicine's MED-RT classification.

How many Bimekizumab products are on the market?

The Bimekizumab drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.

What is the price range for Bimekizumab?

NADAC reference prices for Bimekizumab range from $8016.0364 to $8112.5853 per ML — a 1% difference between cheapest and most expensive.

Which manufacturers make Bimekizumab?

1 manufacturer lists Bimekizumab in NADAC. Ranked by number of NDCs, the largest are UCB, Inc. (3).